Thoracic Aorta Disease Update: Etiology, Diagnosis, and Management

Eric M. Isselbacher, M.D., M.Sc.

Co-Director, MGH Thoracic Aortic Center Director, MGH Healthcare Transformation Lab Associate Professor of Medicine, Harvard Medical School



HARVARD MEDICAL SCHOOL TEACHING HOSPITAL



Presenter Disclosure Information



Corrigan Minehan Heart Center

• No relationships to disclose






- 1. Recognize the risk factors for thoracic aortic aneurysms
- 2. Know the importance of screening family members
- 3. Understand how to choose among the imaging modalities
- 4. Consider the data on medical therapies
- 5. Be aware of the size thresholds for aortic repair
- 6. Be familiar with the available surgical and endovascular options.


Aortic Anatomy 101






Thoracic Aortic Anatomy: Nomenclature





Thoracic Aortic Anatomy: Nomenclature





Be wary of poorly worded imaging reports









Corrigan Minehan Heart Center

- Actual prevalence of thoracic aortic aneurysms is unknown
 - There are no agreed upon definitions of "dilation" or "aneurysm" of the aortic root or ascending aorta
- Diagnosis rate
 - 10-16 cases per 100,000 men per year
 - 5-9 cases per 100,000 women per year
- Diagnosis rate is increasing
 - Aging population
 - Improved diagnostic imaging techniques
 - More frequent use of imaging

Olsson C, et al. Circulation 2006;114:2611 McClure RS, et al. J Thorac Cardiovasc Surg 2018;155:2254-64

Thoracic Aortic Aneurysms: Etiology



Corrigan Minehan Heart Center


- The most common underlying pathology = medial degeneration
 - Fragmentation and loss of elastic fibers
 - Smooth muscle apoptosis
 - Elastic fiber and smooth muscle cell disorganization
 - Mucoid extracellular matrix accumulation
- Aortic wall becomes weak
- Aorta dilates.

Halushka MK, et al. Cardiovasc Pathology 2016; 25:247-257

Medial Degeneration of the Aorta



Corrigan Minehan Heart Center




Normal

Loss of elastic fibers Smooth muscle cell apoptosis Mucoid extracellular matrix accumulation

Thoracic Aortic Anatomy: Aneurysm Involvement by Segment






Root/Ascending (Proximal) vs. Descending (Distal) Aneurysms



Corrigan Minehan Heart Center




Vapnik JS, Kim JB, Isselbacher EM, et al. Am J Cardiol 2016;117:1683-90

Congenital Medial Degeneration: Marfan Syndrome



- Autosomal dominant disorder of connective tissue
- Associated with aneurysms of the aortic root, sparing the ascending aorta
 - Annuloaortic ectasia
- Due to mutations in the gene for fibrillin-1 (FBN1).



Congenital Aneurysms: Bicuspid Aortic Valve



Corrigan Minehan Heart Center

- BAV associated with an increased risk of aortic dilatation, aneurysm, and dissection
- $\approx 50\%$ have a dilated ascending aorta or root
- Originally considered to be "post-stenotic dilatation"
 - Rates similar for AS, AR, or normally functioning BAV
 - Medial degeneration is again the culprit
- Several patterns of involvement:
 - 60% ascending aorta; 10% aortic root; 30% both.

Nistri S, et al. Heart 1999;82:19 DeSa M, et al. J Thorac Cardiovasc Surg 1999;118:588

Familial Thoracic Aortic Aneurysm and Dissection Syndrome



Corrigan Minehan Heart Center

- Medial degeneration is seen in ascending aneurysms or dissection in the absence of known risk factors
 - Cases may be sporadic, but are often familial
 - $-\approx 20\%$ of those with thoracic aortic aneurysms have a family history of a thoracic aneurysm
- Dominant inheritance
 - Marked variability in the expression and penetrance
- Known mutations identified in $\approx 30\%$ of families:
 - ACTA2 (17%), TGFBR2 (2%), MYH11 (1%).

Milewicz DM, Regalado E. https://www.ncbi.nlm.nih.gov/books/NBK1120/

Congenital Thoracic Aortic Aneurysms



Corrigan Minehan Heart Center

• Whether due to MFS, BAV, or a familial thoracic aortic aneurysm syndrome, relatives may be affected

 Therefore, <u>first-degree relatives</u> of affected patients <u>should be screened</u> with an imaging study!

Thoracic Aortic Aneurysms: Less Common Etiologies



- Vascular Ehlers-Danlos syndrome (type IV)
- Loeys-Dietz syndrome
- Turner syndrome
- Vasculitis
 - Takayasu's arteritis
 - Giant cell arteritis
 - IgG4-related aortitis
- Infectious aortitis (mycotic aneurysm)
- Syphilitic aortitis
- Trauma.

Presentation and Detection



- Symptoms are uncommon
- Few are detectable on physical exam
 - Not palpable
 - Diastolic murmur of AR may be present
- Large majority are discovered incidentally
 - Routine CXR, CT, or echocardiogram
- Others go undetected until they dissect or rupture.


Thoracic Aortic Aneurysms: Diagnostic Modalities



- Contrast-enhanced CT scanning (CTA)
- Magnetic resonance imaging (MRI and MRA)
- Echocardiography (TTE and TEE)


Contrast-enhanced CT Scanning: Standard Axial Imaging






A Limitation of Axial CT: The Risk of Mismeasurement





CTA with 3-D Reconstruction Better Defines True Aortic Anatomy





CTA with Planar Reformats



Corrigan Minehan Heart Center




Coronal

Sagittal

MRA (MRI with gadolinium): Aortic Root Aneurysm



Corrigan Minehan Heart Center





Coronal

Sagittal

MRI without Contrast: Black Blood and Bright Blood Imaging









Transthoracic Echocardiography






Transthoracic Echocardiography: Aortic root visualized, but not ascending aorta






Transthoracic Echo: Ascending aorta visualized, but ? underestimate





Transesophageal Echocardiography






Which Modality to Choose: A General Guideline



Routine TAA	Contrast-enhanced CT
Disease of the aortic root	Echocardiogram
Tortuous aorta or arch aneurysm	CTA (3-D reconstruction) or MRA
Allergy to iodinated contrast	MRA
Renal insufficiency	Non-contrast MRI or Non-contrast CT

Thoracic Aortic Aneurysms: Natural History






Rates of Growth




Corrigan Minehan Heart Center



Kim JB, et al. J Am Coll Cardiol 2016;69:1209-19 Coady MA, et al. J Thorac Cardiovasc Surg 1997;113:476-91

Thoracic Aortic Aneurysms: Natural History






Medical Management of Thoracic Aortic Aneurysms





Aortic Ratio 100 150 50 50 100 Months of Follow-up Months of Follow-up Shores J, et al. N Engl J Med 1994; 330:1335-1341



Demonstrated benefit in Marfan syndrome

Beta Blockers



CORRIGAN MINEHAN HEART CENTER





Corrigan Minehan Heart Center

• Trials of beta blockers in TAAs of other etiologies:

• Mainstay of therapy.

Potential Alternative Therapeutic Strategy For Treating Marfan Syndrome




- Hal Dietz, et al
 - In Marfan syndrome, deficiency of fibrillin-1 results in overactivity of TGF- β , which is turn is associated with aortic medial degeneration
- Anti-TGF-β antibody blunted aortic growth in mice
- Previous studies had shown that losartan, an angiotensin II type 1 receptor (AT1) blocker, inhibits activity of TGF-β
- So Dietz et al studied the effect of losartan therapy on aortic root growth in a mouse model of MFS.

Efficacy of Losartan in Mouse Model of MFS: Aortic Growth Over 6 Months



Corrigan Minehan Heart Center




Hagashi J, et al. Science 2006;312:117-121

Efficacy of Losartan in Mouse Model of MFS: Aortic Wall Architecture



Corrigan Minehan Heart Center



Control Marfan

Propranolol

Losartan

Hagashi J, et al. Science 2006;312:117-121





Atenolol vs. losartan for MFS: A <u>randomized</u> <u>blinded controlled</u> trial



Corrigan Minehan Heart Center


- Pediatric Heart Network, Boston Children's Hospital
 - 21 Centers
- 608 subjects, ages 6 months to 25 yr (mean 11 yr)
- Randomized to:
 - Atenolol (mean dose \approx 150 mg in young adults) vs.
 - Losartan (mean dose \approx 85 mg in young adults)
- Followed by echo imaging over 3 years

Lacro RV, et al. N Engl J Med 2014;371:2061-71

Atenolol vs. losartan for MFS: A randomized blinded placebo-controlled trial




Corrigan Minehan Heart Center



Lacro RV, et al. N Engl J Med 2014;371:2061-71

Sobering Reminder






Longer term 9-year trial of losartan vs. atenolol in 128 Marfan patients



Corrigan Minehan Heart Center

FIGURE 2 Effect of Losartan Compared to Atenolol on Aortic Root Dilatation Rate in Subgroups of Marfan Patients



Teixido-Tura, G. et al. J Am Coll Cardiol. 2018;72(14):1613–8

Fluoroquinolone Risk



Corrigan Minehan Heart Center

- Fluoroquinolone antibiotics are known to be associated with an increased risk of tendinitis and tendon rupture
 - Possibly related to an adverse effect on collagen
 - There was an FDA black box warning regarding the risk of tendon rupture
- In 2015 and 2018 three observational studies raised concern that fluoroquinolone antibiotics increase the risk of aortic aneurysm or dissection
 - All reported a twofold increased risk of aortic aneurysm or dissection within 60 days from start of treatment.


Lee C-C, et al. JAMA Intern Med. 2015;175(11):1839-1847 Daneman N, et al. BMJ Open. 2015 Nov 18; 5(11):e010077 Pasternak B, et al. BMJ 2018;360:k678

Fluoroquinolone use and risk of aortic aneurysm and dissection



Corrigan Minehan Heart Center

Cumulative incidence of aortic aneurysm or dissection within 60-day risk period from start of study treatment



U.S. FDA Issued Warning in 12/2018



FDA U.S. FOOD & DR	RUG	A to Z Index Follow FDA En Español Search FDA	٩
Home Food Drugs Medical Drugs Home > Drugs > Drug Safety and Availab		d & Biologics Animal & Veterinary Cosmetics Toba	acco Products
Drug Safety and Availability Drug Alerts and Statements Medication Guides	tears in the aorta bloc	reased risk of ruptures od vessel with iotics in certain patien	
Prog Safe Drug Sho Postmark Providers In patients at increased risk unless there are no other treatment options available.			
Drug Safety Podcasts Safe Use Initiative Drug Recalls Drug Supply Chain Integrity	injection. Fluoroquinolones should not be used in patients available. People at increased risk include thos of the aorta or other blood vessels, high blood p	uoroquinolones for systemic use given by mouth or ts at increased risk unless there are no other treatm se with a history of blockages or aneurysms (abnor pressure, certain genetic disorders that involve bloc t a new warning about this risk be added to the pre- il fluoroquinolones.	nent options mal bulges) od vessel

Educate patients to avoid them





Medical Management in 2022



- Beta blockers are mainstay
- ARBs are good alternative
- If blood pressure room, prescribe both agents
- Target systolic blood pressure 110-125 mmHg
 - Add additional antihypertensives, as needed
- Avoid fluoroquinolones, when possible.

Educate patients about exercise

- Light and moderate aerobic exercise (without sprint or burst episodes) is safe
- When heavy weightlifting requires Valsalva, there is an increase in intrathoracic pressure followed by an increase in SBP to ≥ 300 mmHg
 - So heavy weightlifting and competitive athletics involving isometric exercise should be avoided
 - Those who wish to do weight training should focus on light to moderate weights with lots of reps (if they can breathe or talk while lifting, it should be safe).




MGH

CORRIGAN MINEHAN

HEART CENTER

Thoracic Aortic Aneurysms: Natural History





Weighing the Risk of Aortic Dissection vs. the Risk of Intervention






Rate of Aortic Events vs. Ascending Aortic Diameter



Corrigan Minehan Heart Center




Kim JB, et al. J Am Coll Cardiol 2016; 69:1209-19.

Risk of Aortic Dissection vs. the Risk of Surgery



Corrigan Minehan Heart Center

Mortality of Unoperated Ascending TAA vs. Size



Indications for Intervention





Ascending Aortic Aneurysms: Indications for Aortic Repair



Corrigan Minehan Heart Center

- Idiopathic/sporadic, BAV-related: \geq 5.5 cm
 - − High risk surgery: \geq 6.0 cm
- Genetic (e.g., Marfan, familial): ≥ 5.0 cm
 - Low risk for surgery \geq 4.5 cm
- Rapid expansion
 - ≥ 0.5 cm/year
 - ≥ 0.3 cm/year x several years (extrapolated from ESC guidelines)
- Severe AR: Symptoms or LV dysfunction.

ACC/AHA Guidelines for Management of Thoracic Aortic Disease. J Am Coll Cardiol 2010; 55:e27-e129 A Statement of Clarification From the ACC/AHA. J Am Coll Cardiol 2016; 67:724-731 European Guidelines. Heart J 2014; 35:2873–2926


What Are the Surgical Options?




- Ascending thoracic aortic aneurysms
- Root aneurysms
- Arch aneurysms
- Descending thoracic aortic aneurysms

Ascending Thoracic Aortic Aneurysm: Interposition Tube Graft






Root Aneurysm: Composite Aortic Graft






Root Aneurysm: Valve-Sparing Aortic Root Repair





Arch Aneurysm: Total Arch Replacement









Descending Thoracic Aortic Aneurysm: Open Surgical Repair





Descending Thoracic Aortic Aneurysm: Endovascular Stent-Graft Repair






Left Subclavian to Carotid Transposition or Bypass




Corrigan Minehan Heart Center



Riesenman, PJ, et al. J Vasc Surg 2007;45:90-5.

And Many More Individualized Options






And Finally...



Time is up!





Take Home Points



- 1. Patients with bicuspid aortic valve are at increased risk for root and ascending aneurysms, so make sure to image their aortas
- 2. Screen first-degree relatives of all patients with aortic root and/or ascending aortic aneurysms
- 3. Follow thoracic aortic aneurysms with surveillance imaging
- 4. Beta-blockers remain the mainstay of medical therapy
- 5. The most common threshold for surgery is a diameter of 5.5 cm.

Thoracic Aorta Disease Update: Etiology, Diagnosis, and Management

Eric M. Isselbacher, M.D., M.Sc.

Co-Director, MGH Thoracic Aortic Center Director, MGH Healthcare Transformation Lab Associate Professor of Medicine, Harvard Medical School



HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

